Why the study?
Does pioglitazone attenuate angiotensin II-induced cardiac fibrosis in mouse models with cell-specific PPARgamma deficiency?
Population
Wild-type, cardiomyocyte-specific PPARgamma, and monocyte-specific PPARgamma mice infused with angiotensin II
Design
Preclinical
Authors
Loading...
Macrophage PPARγ mediates pioglitazone's antifibrotic effects in this model; leaves open translation to human diabetic cardiomyopathy.
Does pioglitazone attenuate angiotensin II-induced cardiac fibrosis in mouse models with cell-specific PPARgamma deficiency?
Macrophage PPARgamma activation by pioglitazone prevents myocardial macrophage accumulation and attenuates AngII-induced cardiac fibrosis, suggesting a potential therapeutic target for diabetic cardiomyopathy.
Caglayan et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: